Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting
Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting Presentation by ADHD expert Dr. Ann Childress to highlight Phase 3 findings supporting the potential for true, entire active-day symptom control GlobeNewswire October 23, 2025 KANSAS CITY, Kan., Oct. 23, 2025 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company developing […]